CoChat

Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors

Open access
Sparre‐Ulrich, A H, Hansen, L S, Svendsen, B, Christensen, M, Knop, F K, Hartmann, B, Holst, J J, Rosenkilde, M M · 2016 · British Journal of Pharmacology
Cited by 114

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Background and Purpose: Specific, high potency receptor antagonists are valuable tools when evaluating animal and human physiology. Within the glucose‐dependent, insulinotropic polypeptide (GIP) system, considerable attention has been given to the presumed GIP receptor antagonist, (Pro3)GIP, and its effect in murine studies. We conducted a pharmacological analysis of this ligand including interspecies differences between the rodent and human GIP system. Experimental Approach: Transiently transfected COS‐7 cells were assessed for cAMP accumulation upon ligand stimulation and assayed in competition binding using 125 I‐human GIP. Using isolated perfused pancreata both from wild type and GIP receptor‐deficient rodents, insulin‐releasing, glucagon‐releasing and somatostatin‐releasing properties in response to species‐specific GIP and (Pro3)GIP analogues were evaluated. Key Results: Human (Pro3)GIP is a full agonist at human GIP receptors with similar efficacy (Emax) for cAMP production as human GIP, while both rat and mouse(Pro3)GIP were partial agonists on their corresponding receptors. Rodent GIPs are more potent and efficacious at their receptors than human GIP. In perfused pancreata in the presence of 7 mM glucose, both rodent (Pro3)GIP analogues induced modest insulin, glucagon and somatostatin secretion, corresponding to the partial agonist activities observed in cAMP production. Conclusions and Implications: When evaluating new compounds, it is important to consider interspecies differences both at the receptor and ligand level. Thus, in rodent models, human GIP is a comparatively weak partial agonist. Human (Pro3)GIP was not an antagonist at human GIP receptors, so there is still a need for a potent antagonist in order to elucidate the physiology of human GIP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.13323

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 50

  1. 10.2337/db12-0976 · DOI · Paper page
  2. 10.1111/bph.12445 · DOI · Paper page
  3. 10.1146/annurev.immunol.24.021605.090529 · DOI · Paper page
  4. 10.1016/j.ejphar.2014.08.019 · DOI
  5. 10.1016/0167-0115(83)90135-0 · DOI
  6. 10.1152/ajpendo.1995.269.3.E469 · DOI · Paper page
  7. 10.1113/jphysiol.2009.169078 · DOI · Paper page
  8. 10.1124/jpet.113.208637 · DOI
  9. 10.1073/pnas.0503942102 · DOI · Paper page
  10. 10.1210/en.2013-2043 · DOI
  11. 10.1152/ajpendo.00577.2005 · DOI · Paper page
  12. 10.1016/0165-6147(89)90266-6 · DOI · Paper page
  13. 10.1203/00006450-198004000-00008 · DOI
  14. Ebert R, 1979, Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP‐antiserum in rats, Gastroenterology, 76, 515, 10.1016/S0016-5085(79)80219-X · DOI
  15. 10.1016/S1043-2760(01)00409-X · DOI · Paper page
  16. Gault Victor A, 2007, Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes, Biol Chem, 388, 173
  17. 10.1006/bbrc.2002.6364 · DOI
  18. 10.1007/s00125-002-1028-x · DOI
  19. 10.1007/s00125-007-0710-4 · DOI
  20. 10.1016/S0167-0115(97)00009-8 · DOI
  21. 10.1016/0196-9781(96)00107-6 · doi:10.1016/0196-9781(96)00107-6
  22. 10.1007/s00125-008-1149-y · DOI · Paper page
  23. 10.1016/S0167-4838(01)00181-9 · DOI
  24. 10.1046/j.1365-201X.1996.37259000.x · DOI
  25. 10.1016/j.regpep.2006.03.006 · DOI
  26. 10.1007/s00125-007-0692-2 · DOI
  27. 10.1515/BC.2009.002 · DOI · Paper page
  28. 10.2337/db13-0022 · DOI · Paper page
  29. 10.1016/j.bbrc.2010.12.077 · DOI
  30. 10.1016/j.regpep.2012.08.016 · DOI
  31. 10.1124/pr.111.005223 · DOI · Paper page
  32. 10.1016/j.regpep.2011.12.006 · DOI
  33. 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
  34. 10.1111/j.1476-5381.1993.tb13737.x · DOI · Paper page
  35. 10.1002/psc.839 · DOI
  36. 10.1152/ajpendo.00460.2007 · DOI · Paper page
  37. 10.1111/j.1463-1326.2011.01555.x · DOI · Paper page
  38. 10.2337/db13-1563 · DOI · Paper page
  39. 10.1172/JCI115012 · DOI · Paper page
  40. 10.1073/pnas.0706404104 · DOI · Paper page
  41. 10.1016/j.mce.2014.10.025 · DOI
  42. 10.1093/nar/gkt1143 · DOI · Paper page
  43. Raufman JP, 1991, Exendin‐3, a novel peptide from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed acini from guinea pig pancreas. Description of exendin‐3(9–39) amide, a specific exendin receptor antagonist, J Biol Chem, 266, 2897, 10.1016/S0021-9258(18)49932-2 · DOI · Paper page
  44. 10.1074/jbc.M112.426288 · DOI · Paper page
  45. 10.1016/j.bmcl.2013.04.006 · doi:10.1016/j.bmcl.2013.04.006
  46. 10.2174/0929867321666140716093155 · doi:10.2174/0929867321666140716093155
  47. 10.1002/psc.1250 · DOI
  48. 10.1172/JCI119060 · DOI · Paper page
  49. 10.1016/j.bbapap.2011.04.002 · DOI
  50. 10.1007/s00018-010-0465-9 · DOI · Paper page

Cited by

Metadata

Authors
Sparre‐Ulrich, A. H., Hansen, L. S., Svendsen, B., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & Rosenkilde, M. M.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2015-11-20
Volume
173
Issue
1
Pages
27-38
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2276372335
Cited by
114
References
12
FWCI
7.57
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.